Preferred Drug List Changes for 2010
The Pharmacy and Therapeutics Working Group, a subgroup of the Medical Advisory Council at Paramount, has reviewed and approved changes to the Preferred Drug List.
This Preferred Drug List (PDL) includes brand-name prescription drugs available at the preferred-brand copayment level, if a generic drug is not available. When a brand-name drug on this preferred list becomes generically available, the brand-name drug will no longer be offered at the preferred-brand copayment level. The generic version will be offered at the generic copayment level. The brand-name version, called a multisource brand, may not be covered or may be available at higher copayment levels.
2010 PDL Additions:
- Androgen Drugs – Androgel
- Antipsychotics – Seroquel and Seroquel XR
- Blood Detoxicants – Renvela
- Ophthalmic Anti-Infectives – Vigamox
- Pancreatic Enzymes – Creon
- Antiviral – Tamiflu & Relenza
- Estrogen Replacement – Vivelle Dot and Climara Patch
- Smoking Cessation – Chantix, Buproban, Nicotrol, and Over-the-Counter nicotine replacement products (with a prescription)
- Anticoagulants – Arixtra, lovenox, Innohep, and Fragmin
2010 PDL Deletions:
Respiratory – Ventolin HFANOTE: Prevacid (Proton Pump Inhibitor) and Carac (Dermatological) will be removed once generically available


